{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:23:13Z","timestamp":1785403393781,"version":"3.56.0"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/02"],"award-info":[{"award-number":["MC_UU_00004\/02"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C17093\/A12443"],"award-info":[{"award-number":["C17093\/A12443"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Androgen deprivation therapy (ADT) forms the mainstay of treatment for advanced prostate cancer. Traditionally administered as a luteinising hormone\u2010releasing hormone (LHRH) agonist depot injection, newer options for ADT include transdermal oestradiol patches (tE2) or oral LHRH antagonists. This study aimed to identify whether this is an important choice for men, which treatment men would choose if offered either LHRH agonist injections, tE2 patches or oral LHRH antagonists as ADT, and to explore the factors influencing this decision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects, Patients, and Methods<\/jats:title>\n                    <jats:p>Five focus groups were conducted. A total of 24 men from around the UK participated in discussions, of whom 10 had never had prostate cancer and 14 had early prostate cancer but had not received ADT. Focus groups were co\u2010facilitated with patient and public involvement representatives. Transcripts were analysed using a critical realist thematic analysis approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants reported that having a choice of ADT is important and being involved in making treatment decisions can help men maintain an element of control. Most men expressed a preference to avoid ADT with LHRH agonist injections; 14 of the 24 men reported they would choose an oral LHRH antagonist, eight reported they would choose tE2 patches, and two that they would choose LHRH agonist injections. Participants reported a large number of factors that influenced their treatment choice that were grouped into: (i) side\u2010effects of treatment, (ii) logistical aspects, and (iii) advice from trusted others. Personal preferences between different types of ADT were based on factors that participants identified as important to them, this prioritisation of factors was influenced by participants\u2019 past experiences, current health beliefs, and future expectations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Men wish to have choice of ADT, and many would not choose LHRH agonists injections if there were other ADT options available. This should be considered, as reimbursement committees and guideline\u2010makers consider the role of alternative ADT strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16863","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T06:45:52Z","timestamp":1753944352000},"page":"1037-1047","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preferences between three options for androgen deprivation therapy: a focus group study"],"prefix":"10.1111","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9550-8808","authenticated-orcid":false,"given":"Hannah L.","family":"Rush","sequence":"first","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology University College London  London UK"},{"name":"Guy's and St Thomas\u2019 Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Merrick","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[{"name":"Patient and Public Representatives for the PATCH Trial  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Deighan","sequence":"additional","affiliation":[{"name":"Patient and Public Representatives for the PATCH Trial  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Abdel\u2010Aty","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research  London UK"},{"name":"The Royal Marsden NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla","family":"Alhasso","sequence":"additional","affiliation":[{"name":"The Beatson West of Scotland Cancer Centre  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[{"name":"University of Manchester  Manchester UK"},{"name":"The Christie Hospital NHS Foundation Trust  Manchester UK"},{"name":"Salford Royal Hospital  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2261-3628","authenticated-orcid":false,"given":"Roger","family":"Kockelbergh","sequence":"additional","affiliation":[{"name":"University Hospital of Leicester NHS Trust  Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mangar","sequence":"additional","affiliation":[{"name":"Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D.","family":"Rosen","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research  London UK"},{"name":"The Royal Marsden NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-7012","authenticated-orcid":false,"given":"Duncan C.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-2001","authenticated-orcid":false,"given":"Annabelle","family":"South","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E.","family":"Langley","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2"},{"key":"e_1_2_8_3_1","volume-title":"National Prostate Cancer Audit (NCPA) State of the Nation Report","author":"National Prostate Cancer Audit","year":"2025"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004325"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00100-8"},{"key":"e_1_2_8_6_1","volume-title":"Advanced prostate cancer: developing gonadotropin releasing hormone analogues guidance for industry","author":"Centre for Drug Evaluation and Research","year":"2022"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2312"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0748"},{"key":"e_1_2_8_9_1","unstructured":"ClinicalTrials.gov.Randomized study to evaluate MACE in patients with prostate cancer treated with Relugolix or leuprolide acetate \u2010 NCT05605964. ClinicalTrialsgov.2023"},{"key":"e_1_2_8_10_1","unstructured":"National Institute for Health and Care Research.Payment guidance for researchers and professionals. Version 1.3 nihr.ac.uk website2022. Available from:https:\/\/www.nihr.ac.uk\/documents\/payment\u2010guidance\u2010for\u2010researchers\u2010and\u2010professionals\/27392?pr="},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315617444"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-2166(99)00094-6"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14767430.2022.2076776"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000000388"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13687"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.94"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-7625.2004.00271.x"},{"key":"e_1_2_8_18_1","first-page":"5998","article-title":"Information that affects patients' treatment choices for early stage prostate cancer: a review","volume":"18","author":"Feldman\u2010Stewart D","year":"2011","journal-title":"Can J Urol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/135910539800300304"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7000.299"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732306287599"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1609406919885786"},{"key":"e_1_2_8_23_1","first-page":"E111","article-title":"Feasibility of synchronous online focus groups of rural breast cancer survivors on web\u2010based distress self\u2010management","volume":"45","author":"Lally RM","year":"2018","journal-title":"Oncol Nurs Forum"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732318782167"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1609406917750781"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.10427.2"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/17.1.71"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:17:58Z","timestamp":1767975478000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/bju.16863"],"URL":"https:\/\/doi.org\/10.1111\/bju.16863","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"2025-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}